Targeting Lysine-specific Demethylase 1 to Enhance the Post-transplant Graft-versus-leukemia Effect

靶向赖氨酸特异性去甲基酶 1 增强移植后移植物抗白血病效应

• 批准号: 467033
• 负责人: Yan Yu
• 金额: $ 1.27万
• 依托单位: McMaster University
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-12-01 至 2022-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=467033&lang=en
• 关键词: Adaptive Immunity; Allogenic Transplant; Anti-Tumor Immunity; Cancer Immunotherapy; Epigenetic Therapy; Leukemia; Pre-Clinical Validation; T Cell Immunology; Targeted Therapy; Transplant Immunology

Acute myeloid leukemia (AML) is an aggressive blood cancer with a 5-year survival rate of 21%. AML occurs when the bone marrow produces a large number of unhealthy cells that prevent the growth and functions of normal cells. The only cure for AML patients

急性髓细胞白血病（AML）是一种侵袭性血液癌症，5年生存率为21%。当骨髓产生大量不健康的细胞，阻止正常细胞的生长和功能时，就会发生AML。AML患者的唯一治疗方法